UPDATE: Oppenheimer Starts Gain Therapeutics (GANX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BTIG Starts Gain Therapeutics (GANX) at Buy
April 12, 2021 5:31 AM EDTBTIG analyst Thomas Shrader initiates coverage on Gain Therapeutics (NASDAQ: GANX) with a Buy rating (from $30.00).
For an analyst ratings summary and ratings history on Gain Therapeutics click here. For more ratings news on Gain Therapeutics click here.
Shares of Gain Therapeutics closed at $13.98 yesterday.
... More